---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-311294"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T13:58:30.659870+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction

## Summary
- Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
- Stockholders approved proposal to issue New PIPE Shares and Pre-Funded Warrant under Sept 28 securities purchase agreement (2,049,724 For).
- Stockholders approved adjournment proposal (2,058,277 For).
- Initial MVID proof-of-concept trial shows crofelemer can reduce total parenteral support by up to 37% in infants with microvillus inclusion disease.
- Company met with FDA on Oct 2, 2025 for advice on expedited approval pathway for crofelemer for MVID; no approved treatments exist.

## SEC filing metadata
- accession: 0001193125-25-311294
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/0001193125-25-311294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/jagx-20251208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-311294
- JSON: https://secwatch.observer/filing/0001193125-25-311294.json
- Plain text: https://secwatch.observer/filing/0001193125-25-311294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.